Bicycle Therapeutics Ltd (BCYC) - Total Assets
Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) holds total assets worth $763.95 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BCYC book value for net asset value and shareholders' equity analysis.
Bicycle Therapeutics Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data.
Bicycle Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Bicycle Therapeutics Ltd's total assets of $763.95 Million consist of 97.1% current assets and 3.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 91.9% |
| Accounts Receivable | $35.65 Million | 3.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BCYC company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bicycle Therapeutics Ltd's current assets represent 97.1% of total assets in 2024, an increase from 95.4% in 2016.
- Cash Position: Cash and equivalents constituted 91.9% of total assets in 2024, up from 79.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 3.7% of total assets.
Bicycle Therapeutics Ltd Competitors by Total Assets
Key competitors of Bicycle Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Bicycle Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.66 | 17.13 | 6.73 |
| Quick Ratio | 10.66 | 18.16 | 6.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $669.54 Million | $909.79 Million | $132.59 Million |
Bicycle Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Bicycle Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.24 |
| Asset Growth Rate (YoY) | 60.7% |
| Total Assets | $956.87 Million |
| Market Capitalization | $228.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bicycle Therapeutics Ltd's assets below their book value (0.24x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Bicycle Therapeutics Ltd's assets grew by 60.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Bicycle Therapeutics Ltd (2016–2024)
The table below shows the annual total assets of Bicycle Therapeutics Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $956.87 Million | +60.73% |
| 2023-12-31 | $595.34 Million | +44.99% |
| 2022-12-31 | $410.61 Million | -14.42% |
| 2021-12-31 | $479.79 Million | +197.73% |
| 2020-12-31 | $161.15 Million | +46.24% |
| 2019-12-31 | $110.19 Million | +35.00% |
| 2018-12-31 | $81.63 Million | +10.30% |
| 2017-12-31 | $74.00 Million | +525.27% |
| 2016-12-31 | $11.84 Million | -- |
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more